Joel Trugman, M.D., is a neurologist and pharmaceutical physician executive with a record of success in leading development programs as well as designing and implementing novel clinical trial designs. At Allergan/AbbVie, he was Associate Vice President, Neuroscience Development, and led the clinical development of two oral CGRP receptor antagonists for the treatment of migraine with global approvals: ubrogepant (Ubrelvy: FDA approval 2019) and atogepant (Qulipta: FDA approval 2021, EMA approval 2023). He developed and executed a novel migraine trial design administering ubrogepant during the prodrome (pre-headache phase of migraine), demonstrating that the development of headache can be prevented (The Lancet, 2023), a transformational concept in the treatment of acute migraine. Prior to that, Joel worked in Clinical Development at Forest Labs and Actavis on multiple CNS programs. Before joining Forest Labs, Joel was Associate Professor of Neurology at the University of Virginia School of Medicine where his lab studied the functional anatomy of basal ganglia circuits as they relate to Parkinson’s disease and antipsychotic drug action. He completed his residency in Adult Neurology at the University of Minnesota and fellowship in Neuropharmacology at the University of Virginia. He received his M.D. degree from Boston University School of Medicine.

